OTCPK:ARLZQ - Post by User
Post by
biggerron Apr 12, 2017 9:06pm
336 Views
Post# 26115707
It's Zontivity or bust
It's Zontivity or busthttps://www.bloomburton.com/research/ARLZ20170410.pdf
"Aralez is planning a phased re-launch of Zontivity in the U.S. starting in April 2017 targeting the severe PAD market. We estimate Zontivity could achieve net revenues of $363 MM by 2023 in the U.S. and Canada in our base case"
ARZ won't repeat the mistake of Merck of offering Zontivity to the ACS(Acute Coronary Syndrome) patients, instead, it will offer it for the PAD(Peripheral Arterial Disease) patients where it has much better chances of being accepted, so shorts beware, ha